B and T lymphocyte attenuator marker for use in adoptive T-cell therapy
BTLA-positive (“BTLA+”) lymphocyte signaling drives T cells and kills tumors. BTLA functions as a positive modulator of anti-tumor (anti-melanoma) T cell responses, The BTLA+ T cell responds against tumor or cancer cells, and, in cancer patients respond better to IL-2 than BTLA-negative cells. Hence, the BTLA-positive T cell in cancers is a positive marker for selection of enriched anti-tumor-cancer reactive T cells and can be used or applied for adoptive T-cell therapy or for therapeutic purposes.
1. A method of treating a cancer patient comprising administering to the patient an effective amount of anti-cancer T-cells wherein the anti-cancer T-cells are selected or enriched for BTLA-positive T-cells.
2. The method of claim 1 , wherein the patient has a melanoma.
3. The method wherein the patient has metastatic melanoma.
4. The method of claim 1 , further comprising administering IL-2 to the patient.
5. The method of claim 1 , further comprising administering a platelet and red blood cell transfusion to the patient.
6. The method of claim 1 , wherein the patient has been lymphoablated prior to the administering.
7. The method of claim 1 , wherein the T-cells are obtained from the patient.
8. The method of claim 7 , wherein the T-cells are obtained from tumor sample from the patient.
9. The method of claim 1 , wherein the T-cells are expanded in vitro prior to said administering.
10. The method of claim 1 , wherein the T-cells comprise CD8 + , TEM or TEFF cells.
11. The method of claim 1 , further comprising obtaining a population of anti-cancer T-cells and selecting for BTLA-positive T cells prior to the administering step.
12. The method of claim 1 , wherein the patient is administered 8-150×10 9 cells.